Hi @Vinneys,
This is an excerpt from the JPM website relevant to the conference held this year in Jan 23.
“Birthplace of Deals
The Conference is also the birthplace of a lot of deals, with companies announcing major transactions in the run-up.
Building off the momentum at the end of 2022, when J.P. Morgan's Global Head of Health Care Investment Banking, Mike Gaito, and his team led the industry’s biggest merger — the $28 billion sale of Horizon Therapeutics to Amgen — more than $3.5 billion worth of deals were announced to coincide with the Conference.
Chiesi’s $1.25 billion acquisition of rare disease drugmaker Amryt Pharma and AstraZeneca’s $1.3 billion buyout of CinCor Pharma, which gives it access hypertension and kidney disease treatments, were among the highlights.
These biotech buyouts gave the Conference a jumpstart, suggesting that the uptick in M&A activity that began in the second half of last year could stick around.
The M&A environment should “be really vibrant in 2023,” said Gaito, who opened the conference”
https://www.jpmorgan.com/solutions/cib/insights/healthcare-conference-highlightsI would anticipate that major pharmaceutical companies will already be researching the attendees (IHL) and their potential. A fantastic business to business marketing opportunity.
It has been a long time since Jul 19 when I first invested!
Hopefully exciting times coming.
